Cumulative suppressive index as a predictor of relapse free survival and overall survival in Human Papilloma Virus ‐negative oral squamous cell carcinomas with negative resection margins

Head & Neck ◽  
2020 ◽  
Author(s):  
Lauren Hum ◽  
Daniel Bethmann ◽  
Zipei Feng ◽  
Shu‐Ching Chang ◽  
Alexander Eckert ◽  
...  
Keyword(s):  
Overall Survival ◽  
Human Papilloma Virus ◽  
Squamous Cell ◽  
Squamous Cell Carcinomas ◽  
Resection Margins ◽  
Relapse Free Survival ◽  
Papilloma Virus ◽  
Free Survival ◽  
Oral Squamous Cell Carcinomas

TP53 mutation and human papilloma virus status of oral squamous cell carcinomas in young adult patients

Oral Diseases ◽  
2013 ◽  
Vol 20 (6) ◽  
pp. 602-608 ◽  
Author(s):  
BJM Braakhuis ◽  
MM Rietbergen ◽  
M Buijze ◽  
PJF Snijders ◽  
E Bloemena ◽  
...  
Keyword(s):  
Young Adult ◽  
Human Papilloma Virus ◽  
Squamous Cell ◽  
Tp53 Mutation ◽  
Squamous Cell Carcinomas ◽  
Adult Patients ◽  
Papilloma Virus ◽  
Oral Squamous Cell Carcinomas ◽  
Human Papilloma Virus Status

O196. Human papilloma virus in oral squamous cell carcinomas from young non-smokers in the region of Northern Greece

2009 ◽  
Vol 3 (1) ◽  
pp. 121
Author(s):  
A.K. Kyrgidis ◽  
R.V. Valeri ◽  
G.K. Koloutsos ◽  
A.N. Ntomouchtsis ◽  
K.V. Vahtsevanos ◽  
...  
Keyword(s):  
Human Papilloma Virus ◽  
Squamous Cell ◽  
Squamous Cell Carcinomas ◽  
Northern Greece ◽  
Papilloma Virus ◽  
Oral Squamous Cell Carcinomas

Human Papilloma Virus DNA Detection, p53 and Ki67 Expression in Penile Verrucous and Squamous Cell Carcinomas in the Same Patient

2009 ◽  
Vol 36 (7) ◽  
pp. 417-418 ◽  
Author(s):  
Vincenzo Gentile ◽  
Alessandro Sciarra ◽  
Ulderico Parente ◽  
Maria R. Cardillo ◽  
Alessandra Pierangeli ◽  
...  
Keyword(s):  
Human Papilloma Virus ◽  
Squamous Cell ◽  
Dna Detection ◽  
Squamous Cell Carcinomas ◽  
Papilloma Virus ◽  
Ki67 Expression

Comparison of the seventh and eighth editions of the American Joint Committee on Cancer (AJCC) staging for oropharyngeal squamous cell carcinomas (OPSCC): A Surveillance, Epidemiology and End Results Program (SEER) database analysis.

2019 ◽  
Vol 37 (15_suppl) ◽  
pp. e17538-e17538
Author(s):  
Sumita Trivedi ◽  
Haocan Song ◽  
Yuan Liu ◽  
Conor Ernst Steuer ◽  
William Stokes ◽  
...  
Keyword(s):  
Overall Survival ◽  
Head And Neck ◽  
Squamous Cell ◽  
Disease Free Survival ◽  
Squamous Cell Carcinomas ◽  
Stage I ◽  
Seer Database ◽  
Free Survival ◽  
Ajcc Staging ◽  
Disease Free

e17538 Background: The recently released eighth edition of the American Joint Committee on Cancer (AJCC) Staging Manual, Head and Neck Section, incorporates significant changes to the prior seventh edition. The changes reflect the improved understanding of tumor biology, prognostic factors and molecular markers that effect outcomes in Head and Neck cancers. A key update restages OPSCC by human papilloma virus (HPV) positive and negative cancers as data demonstrated that these tumors have significantly different biology and outcomes. Methods: Using SEER data from 2004 – 2014, we identified male patients with squamous cell carcinomas of the tonsil, base of tongue and soft palate aged between 21 and 64 years old (those clinical characterizes were considered as surrogate markers for HPV positive status). We classified them by the AJCC 8th edition staging for HPV positive OPSCC and by AJCC 7th edition staging. The prediction performance by two staging editions were compared regarding overall survival (OS) and Disease free survival (DFS). Kaplan-Meier method and Cox proportional hazard model were applied, and the discrimination performance was measured by the concordance statistics (C-statistics). Results: A total of 8202 eligible patients were included in the analysis with a median follow up period of 51 months. 7415 (90.4%) patients had previously received radiation and 7038 (85.8%) patients had previously received chemotherapy. The median age of patients was 56 years. Distribution of stage I disease increased from 2% to 19.6% in AJCC 8th edition. 10-year overall survival (OS) for AJCC 8th stages I (74%), II (78%), III (55%) and IV (32%). Using Stage I as reference, the hazard ratio for stage II, III, and IV is 0.98 (95%CI: 0.87-1.09), 2.29 (95%CI: 2.04-2.57), and 5.88 (95%CI: 4.96-6.98). Similar results were noted for ten year disease free survival. The C-statistics measured overall discrimination for 8th edition is 0.68 and 0.63 for the 7th edition (P < 0.001). Conclusions: Based on this SEER analysis, the overall performance of discrimination improved from AJCC 7th to 8th edition; but in this study population, AJCC 8th edition does not distinguish stage I and II sufficiently as expected as it does for stages III and IV disease. Limitations of the SEER database include the surrogate for P16 status and under reported and incomplete data.

Sign in / Sign up

Export Citation Format

Share Document